IMI focused on the needs common to pharmaceutical industry and patients

ICT-enabled solutions for affordable personalised health services
Ann Martin – IMI JU
Innovative Medicines Initiative

“Applicants consortium”
IMI beneficiaries

“EFPIA consortium”
EFPIA in kind contribution
(no public funding)
IMI projects so far

• Pre-competitive research in Efficacy, Safety, Education&Training, Knowledge Management
• Call 2008: 15 projects initiated
• Call 2009: 9 full project proposals in preparation
Knowledge Management @ IMI

2 objectives for the data pooling and processing infrastructure:

• Translational Knowledge Management supporting Safety and Efficacy projects by ensuring implementation of standards and integration of the project results into the KM platform

• Knowledge Management Platform – an integrated biomedical data platform with interactive scientific exploration tools
Current situation

R-language, SQL
SBML
MAGE-ML
CELLML
GO
OBO Foundry

basic research

clinical research

health care

HL7
DICOM
LOINC
SNOMED

SAS
CDISC
Meddra
Snomed
LOINC

ETP 2010, Brussels
Drug Disease Modelling Library and Framework

- Improve Modelling & Simulation (M&S) activities for model based drug discovery and development
- Create common ontology to describe pharmacometric & mechanistic modelling
- Develop library for pharmacometric, statistical and systems biology models
- Create software interoperability framework

→ Improved M&S infrastructure for public/private institutions
→ Releases data, models & framework in public domain

ETP 2010, Brussels
Open Pharmacological Space

- Data, tools and workflows for drug discovery i.e. drug targets and drugs for public/private institutions
- Data from public/private institutions shared openly with secure and stable service models
- Biological and chemical structure data relevant to early drug discovery
- Open source data infrastructure, free for the scientific community

→ Improved capabilities for drug discovery for public and private institutions
Electronic Health Records

- Sustainable framework for interoperability and secondary use of EHR data
- Focus on clinical trial protocol feasibility, patient recruitment, drug safety, and cost effectiveness
- Clear value demonstration through execution of pilot projects
  - demonstrate integrity, security, performance & scalability
  - across European regions and/or countries
  - in an ethical and safe way complying with legal requirements
  - designed to protect patient confidentiality
- Provide forum for emerging EHR initiatives across Europe through consistent adoption of best practices

→ Improved infrastructure for clinical research, convergence clinical care and research
Conclusion

• Translational Knowledge Management
• Improved M&S infrastructure for public/private institutions, releases data, models & framework in public domain
• Improved capabilities for drug discovery for public and private institutions
• Improved infrastructure for clinical research, convergence clinical care and research

2-way Interoperability of Standards to the GOLD Standard?

to advance predictivity in safety and efficacy research